[{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"University of New South Wales","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AZR-MD-001","moa":"Mitosis","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ University of New South Wales","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ University of New South Wales"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Syneos Health | Cliantha Research","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AZR-MD-001","moa":"Mitosis","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ Syneos Health | Cliantha Research","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ Syneos Health | Cliantha Research"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"University of New South Wales","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"AZR-MD-001","moa":"Mitosis","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ University of New South Wales","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ University of New South Wales"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Avania","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AZR-MD-001","moa":"Mitosis","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ Avania","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ Avania"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"CUREator","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Selenium Sulfide","moa":"quaternary ammonium derivatives","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ CUREator","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ CUREator"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Selenium Sulfide","moa":"quaternary ammonium derivatives","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Selenium Sulfide","moa":"quaternary ammonium derivatives","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Selenium Sulfide","moa":"quaternary ammonium derivatives","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ Undisclosed"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Selenium Sulfide","moa":"quaternary ammonium derivatives","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ OrbiMed Advisors","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Azura Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Selenium Sulfide","moa":"quaternary ammonium derivatives","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III","graph3":"Azura Ophthalmics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Azura Ophthalmics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Azura Ophthalmics \/ Undisclosed"}]